FN2 Earnings Intelligence
Molina Healthcare, Inc. earnings overview
Latest Molina Healthcare, Inc. (MOH) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Molina Healthcare, Inc.
Molina's Q3 read-through is mixed: management reaffirmed 2026 guidance and cited Medicaid rate and Florida contract support, but medical-cost, enrollment and contract-timing risks remain.
Molina Healthcare, Inc.
Molina Healthcare's Q2 2026 results mark a shift from cautious to confident. After maintaining guidance in Q1, management raised full-year EPS guidance from at least $5.00 to at least $5.25, driven by Medicare dual-eligible products that contributed $1.25 per share with a 1.4% pretax margin. Medicaid margins appear to be stabilizing at a 92.7% MCR with a 5% medical cost trend, supporting management's view that 2026 is a trough year. However, the stock fell 9.7% in the reaction window (vs. SPY -1.2%), with a further 2.9% drift lower, as investors weighed a $0.75 per-share Marketplace loss from adverse acuity mix, a $1.5 billion near-term margin drag from the Florida CMS contract, and the reality that managed Medicaid remains underfunded by roughly 300 basis points. The path to $64 billion in premium revenue by 2029 through RFP wins, M&A, and AI-driven efficiency is ambitious but…
Molina Healthcare, Inc.
Molina delivered a solid Q1 2026, handily beating adjusted EPS ($2.35 vs $1.90 est) on a favorable medical cost trend and record-low low/no utilizers, and it maintained rather than lowered full-year guidance of roughly $42B premium revenue and at least $5 adjusted EPS. The market rewarded the print with a roughly 14% single-session gain against a flat S&P 500. The main swing factors to watch through 2026 are the revised-up Medicaid attrition (6%, double the prior 2%), the pacing of off-cycle and retroactive rate adjustments, and the build-out of the $6B-run-rate Florida Kids contract, which management expects to lift embedded earnings over the next two years.
Molina Healthcare, Inc.
Molina's growth case rests on Medicaid contract wins, integrated dual-eligible products and embedded earnings, but the evidence is balanced by medical-cost pressure, retroactive adjustments and execution risks.
Molina Healthcare, Inc.
The quarter weakens the case for near-term earnings resilience: Marketplace utilization and limited risk-corridor protection drove a large EPS miss and a lower outlook. The longer-term growth case rests on Medicaid and Medicare dual-eligible expansion, rate advocacy, cost controls, and disciplined M&A, but those drivers must offset medical-cost and membership pressure.
Molina Healthcare, Inc.
The transcript supports a mixed test of the growth hypothesis: contract wins, embedded earnings and acquisition opportunities support longer-term growth, but the current quarter showed cost pressure and lower guidance that weaken near-term evidence.
Molina Healthcare, Inc.
The supplied analysis supports a constructive but qualified view: contract wins, Medicaid rate updates, and embedded-earnings growth improve Molina's trajectory, while Marketplace normalization, the Virginia contract loss, and medical-cost assumptions remain material tests.
Molina Healthcare, Inc.
The supplied analysis supports a constructive but conditional view: contract wins, ConnectiCare, Marketplace growth and expected rate actions can support earnings growth, but the thesis depends on medical-cost control, adequate rates and successful execution.
Get the MOH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.